Follow-up testing of rodent carcinogens not positive in the standard genotoxicity testing battery: IWGT workgroup

Peter Kasper1, Yoshifumi Uno, Robert Mauthe

  • 1Federal Institute for Drugs and Medical Devices (BfArM), Kurt-Georg-Kiesinger-Allee 3, D-53175 Bonn, Germany.

Mutation Research
|November 25, 2006
PubMed

Insights

This study proposes a strategy for genotoxicity testing when standard tests are negative but tumors form in rodents. It outlines when and how to conduct follow-up genetic toxicology studies to determine the mode of action for carcinogenesis.

Area of Science:

  • Toxicology
  • Genetic Toxicology
  • Carcinogenesis

Background:

  • The standard genotoxicity test battery is crucial for determining the mode of action (MOA) of carcinogenesis.
  • Limitations exist in the standard genotoxicity testing battery.
  • Expert groups have convened to develop strategies for genotoxicity testing beyond the standard battery.

Purpose of the Study:

  • To provide guidance on a common strategy for genotoxicity testing beyond the current standard battery.
  • To discuss when and what type of additional genetic toxicology studies are appropriate for tumorigenic agents negative in the standard battery.
  • To develop a decision tree for follow-up testing.

Main Methods:

  • Discussion of the role and limitations of standard genotoxicity tests.
  • Consideration of the entire toxicological profile of a compound.
  • Analysis of case studies to understand practical applications of additional testing.
  • Formulation of a decision tree for additional genetic toxicology assays.

Main Results:

  • A framework for follow-up genotoxicity testing was developed.
  • Case studies illustrated the practical application of additional testing.
  • A decision tree was formulated to guide the selection of additional genetic toxicology assays.
  • The importance of considering the complete toxicological profile was emphasized.

Conclusions:

  • Additional genetic toxicology studies are valuable when standard tests are negative but tumors are observed.
  • A comprehensive approach considering the entire toxicological profile is necessary.
  • The developed decision tree aids in determining carcinogenic MOA and establishing weight of evidence (WOE).

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
In vitro Mutagenesis01:16

In vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.